Phase III, Multicenter, Randomized, Assessor-blind Study to Evaluate the Safety and Efficacy of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.
Overview
- Phase
- Phase 3
- Intervention
- Sodium picosulphate, light magnesium oxide and anhydride citric acid.
- Conditions
- Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.
- Sponsor
- Laboratorios Casen-Fleet S.L.U.
- Enrollment
- 547
- Locations
- 15
- Primary Endpoint
- Percentage of subjects that achieve 'excellent' or 'good' cleansing in the Fleet® Grading Scale for Bowel Cleansing.
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to determine any significant differences in the efficacy and acceptability between CitraFleet and Klean Prep® (polyethylene glycol) for the preparation of gastrointestinal subjects undergoing a colon examination.
Detailed Description
The composite principal objective of the current study will therefore be, to determine any significant differences in the joint variable of efficacy and acceptability between CitraFleet and Klean Prep® (polyethylene glycol) for the preparation of subjects undergoing a colon examination. The evaluation will be carried out by two blinded assessors, independent of the investigator who performed the procedure (endoscopist investigator). It will be assessed from images of different sections of the colon: cecum, ascending, transverse, descending and rectum and subsequent confirmation by Principal Investigator if an agreement has been reached between the two blinded assessors or whether it is necessary to reach consensus. The evaluation of the subject's acceptability will be assessed using a 5 point scale which assesses the difficulty of taking the product, the degree of discomfort caused by it, and the taste of the drug. The secondary objective is to evaluate the safety of CitraFleet. In addition a second exploratory arm of CitraFleet was included in this study (CitraFleet Exploratory arm). The study is not powered to make formal statistical comparisons for this arm. Exploratory assessment of this arm against the main CitraFleet regimen and Klean-Prep will be made in order to run future trials design with this schedule.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who are between 18 and 80 years of age.
- •Subjects undergoing complete colonoscopy and therefore require prior preparation with either Klean Prep® or CitraFleet.
- •Subjects capable of maintaining appropriate oral hydration during the intestinal preparation process.
- •Subjects that have provided written informed consent.
- •Subjects in whom the use of any of the study drugs (KleanPrep®,CitraFleet) is not contraindicated.
- •Subjects who can communicate with the study personnel and comply with study requirements.
- •Subjects undergoing a complete exploratory diagnostic colonoscopy for the first time.
Exclusion Criteria
- •Severe renal insufficiency.
- •Congestive heart failure.
- •Gastrointestinal obstruction, gastric retention, intestinal perforation and/or ileus.
- •Megacolon and/or toxic colitis.
- •Nausea and/or vomiting and/or abdominal pain.
- •Severe dehydration.
- •Hypermagnesemia.
- •Rhabdomyolysis.
- •Pregnant women.
- •Subjects who have participated in a clinical trial in the previous 30 days.
Arms & Interventions
Citrafleet
The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.
Intervention: Sodium picosulphate, light magnesium oxide and anhydride citric acid.
Klean Prep
The day prior to the colonoscopy from 16:00h to 20:00h.
Intervention: Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.
Citrafleet Exploratory
The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.
Intervention: Sodium picosulphate, light magnesium oxide and anhydride citric acid.
Outcomes
Primary Outcomes
Percentage of subjects that achieve 'excellent' or 'good' cleansing in the Fleet® Grading Scale for Bowel Cleansing.
Time Frame: 24 hours
Percentage of subjects who find the agent easy to take or tolerable using a 5 point scale which assesses, the difficulty of taking the product, the degree of discomfort caused by it, and the taste of the drug, recorded in the subject questionnaire
Time Frame: 24 hours
Secondary Outcomes
- Frequency of adverse reactions.(24 hours)